Elizabeth M. Brunt, MD

Elizabeth M. Brunt, MD

Emeritus Professor, Pathology and Immunology


  • Anatomic & Molecular Pathology


  • MD: University of Texas, Medical Branch, Galveston, TX
  • Residency and Fellowship, Anatomic Pathology: Washington University School of Medicine, St Louis, MO

Board Certifications

  • Anatomic Pathology
  • Clinical Pathology


  • Best Doctors in Missouri
  • Distinguished Service Award, American Association for the Study of Liver Disease

Clinical Interests

  • Liver Pathology
  • Nonalcoholic Fatty Liver Disease
  • Hepatocellular Carcinoma

Research Interests

My research has focused on histopathologic features of nonalcoholic fatty liver disease, specifically, grading and staging the lesions of this significant disease, and its findings with other forms of chronic liver disease. I have worked to help define essential lesions necessary for the definition/diagnosis of nonalcoholic steatohepatitis, as well as the unique types of fibrosis that occur in this entity. I was co-chair of the pathology committee of the NIH sponsored NASH Clinical Research Network, was a co-author for the scoring system most often utilized for clinical treatment trials for NASH worldwide, and have participated in NIH-sponsored therapeutic interventional trials of NASH; I was also a member of pathology committees for NIH-sponsored studies for treatment of HCV and HBV. I have participated as the pathology representative for publication of Practice Guidance for NASH for the AASLD. I recently worked with a large group of international pathologists as the lead author to define a working terminology for an unusual form of primary liver cancer in order for reproducible epidemiologic, clinical and molecular studies to occur.
Selected Publications
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999: 94(9): 2467-2474. PMID: 10484010
Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003: 16(1): 49-56. PMID: 12527713
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005: 41(6): 1313-1321. PMID: 15915461
Brunt EM, Kleiner DE, Wilson LA, Ünalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA, NASH Clinical Research Network. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research Network. Hepatology 2009:49(3): 809-820. PMID: 19142989
Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic Diagnosis of NAFLD: distinct clinicopathologic meanings. Hepatology 2011: 53(3): 810-820. PMID: 21319198
Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A; NASH Clinical Research Network. Histological Abnormalities in Children with Nonalcoholic Fatty Liver Disease and Normal or Mildly Elevated Alanine Aminotransferase Levels. J Pediatr 2014: 164: 707-713. PMID: 24360992
Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 Immunoreactivity Predicts Prognosis in Western Hepatocellular Carcinoma Patients but Is a Rare Event: A Study of 236 Cases. Am J Surg Pathol 2014: 38: 966-72. PMID: 24805857
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; for the NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2014:385(9972) 956-965. PMID: 25468160
Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Park, Y-N, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N. cHCC-CCA: Consensus terminology for primary liver carcinoma with both hepatocytic and cholangiocytic differentiation. Hepatology 2018;68(1):113-126. PMID:29360137
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and managament of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1):328-357. PMID:28714183

Billie Charlton